Abstract:Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer (NK) cells are emerging tools for cancer therapy. However, only subpopulations of NK cells that are differentially controlled by inhibitory receptors exert reactivity against particular cancer types. How to leverage the complete anti-tumor potential of all NK cell subsets without favoring the emergence of NK cell-resistant tumor cells remains unresolved. Methods We performed a genome-wide CRISPR/Cas9 knockout resistance screen in melanoma cells in co-cultures with human primary NK cells. We comprehensively evaluated factors regulating tumor resistance and susceptibility by focusing on NK cell subsets in an allogenic setting. Moreover, we tested therapeutic blocking antibodies currently used in clinical trials. Results Melanoma cells deficient in antigen-presenting or the IFNγ-signaling pathways were depleted in remaining NK cell-co-cultured melanoma cells and displayed enhanced sensitivity to NK cells. Treatment with IFNγ induced potent resistance of melanoma cells to resting, IL-2-cultured and ADCC-activated NK cells that depended on B2M required for the expression of both classical and non-classical MHC-I. IFNγ-induced expression of HLA-E mediated the resistance of melanoma cells to the NKG2A + KIR − and partially to the NKG2A + KIR + NK cell subset. The expression of classical MHC-I by itself was sufficient for the inhibition of the NKG2A − KIR + , but not the NKG2A + KIR + NK cell subset. Treatment of NK cells with monalizumab, an NKG2A blocking mAb, enhanced the reactivity of a corresponding subset of NK cells. The combination of monalizumab with lirilumab, blocking KIR2 receptors, together with DX9, blocking KIR3DL1, was required to restore cytotoxicity of all NK cell subsets against IFNγ-induced resistant tumor cells in melanoma and tumors of different origins. Conclusion Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.

Cancer Cell Resistance to IFNγ Can Occur Via Enhanced Double-Strand Break Repair Pathway Activity.

Dual role of interferons in tumor immunology

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Double-edged Roles of IFNγ in Tumor Elimination and Immune Escape

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line Via a RhoGDI2/Rac1/NF-κB Signaling Pathway.

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

IFN-γ Induces the Upregulation of RFXAP Via Inhibition of Mir-212-3p in Pancreatic Cancer Cells: A Novel Mechanism for IFN-γ Response.

Interferon gamma induces higher neutrophil extracellular traps leading to tumor-killing activity in microsatellite stable colorectal cancer

Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction

Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation

IFNγ-dependent remodelling of the myeloid landscape underlies control of IFNγ-insensitive tumours

The Diverse Pancreatic Tumor Cell-Intrinsic Response to IFNγ is Determined by Epigenetic Heterogeneity.

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer

Tumor-intrinsic RGS1 Potentiates Checkpoint Blockade Response Via ATF3-IFNGR1 Axis

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research

Low-dose IFN-γ induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer

Interferon Gamma in Cancer Immunotherapy